THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM

被引：0
|
作者：
Lebmeier, M. [1 ]
Pericleous, L. [1 ]
Drost, P. [2 ]
Dequen, P. [3 ]
Ouwens, M. [4 ]
Bergman, G.
Baig, H. [1 ]
机构：
[1] Bristol Myers Squibb Pharmaceut Co, Uxbridge, Middx, England
[2] Bristol Myers Squibb, Braine Ialleud, Belgium
[3] Mapi Values, Bollington, Cheshire, England
[4] Mapi Values, Houten, Netherlands
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72190-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of abatacept in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) or tumor necrosis factor-alpha inhibitors (anti-TNFs): A Canadian perspective
    Maier-Moldovan, M.
    Yuan, Y.
    Maclean, R.
    L'Italien, G. J.
    VALUE IN HEALTH, 2008, 11 (03) : A257 - A257
  • [22] Cost-Effectiveness of Methotrexate and Sulfasalazine in Rheumatoid Arthritis: A Comparative Study
    Bhatt, K.
    Girish, K.
    Pundarikaksha, H. P.
    Tamboli, T.
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 : S54 - S54
  • [23] Cost-effectiveness of rituximab (Mabthera) compared with abatacept (Orencia) for the treatment of moderate/severe rheumatoid arthritis (RA) in the united kingdom
    Lewis, G.
    Kielhorn, A.
    Diamantopoulos, A.
    VALUE IN HEALTH, 2007, 10 (06) : A249 - A250
  • [24] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
    Choi, HK
    Seeger, JD
    Kuntz, KM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (10): : 2316 - 2327
  • [25] A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
    Brodszky, V
    Borgstrom, F.
    Arnetorp, S.
    Pentek, M.
    Gulacsi, L.
    VALUE IN HEALTH, 2008, 11 (06) : A549 - A550
  • [26] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-α antagonists
    Vera-Llonch, Montserrat
    Massarotti, Elena
    Wolfe, Frederick
    Shadick, Nancy
    Westhovens, Rene
    Sofrygin, Oleg
    Maclean, Ross
    Li, Tracy
    Oster, Gerry
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (09) : 1745 - 1753
  • [27] EFFICACY OF TOFACITINIB IN COMBINATION WITH METHOTREXATE COMPARED TO BIOLOGICAL DMARDS IN COMBINATION WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATE: OVERVIEW OF SYSTEMATIC REVIEW
    Reyes, J. M.
    Rodriguez, A.
    VALUE IN HEALTH, 2015, 18 (03) : A1555 - A1555
  • [28] Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis
    Lee, S-S.
    Park, Y-W.
    Park, J. J.
    Kang, Y. M.
    Nam, E. J.
    Kim, S. I.
    Lee, J. H.
    Yoo, W-H.
    Lee, S-I.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2009, 38 (01) : 11 - 14
  • [29] Abatacept (CTLA4IG) in combination with methotrexate demonstrates sustained improvements in patient-reported outcomes over two years in rheumatoid arthritis patients with inadequate response to methotrexate
    Li, T
    Maclean, R
    Nuamah, I
    Becker, J
    VALUE IN HEALTH, 2005, 8 (03) : 343 - 343
  • [30] Safety and efficacy of abatacept over 4 years of treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate in the AIM trial
    Kremer, J. M.
    Russell, A. S.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S308 - S309
12345